Amgen wins Sjogren's trial as Jefferies raises target for Amgen stock

Published on 10/02/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 9.50 percent to USD 10.05 billion. Amgen stock costs EUR 364.45 on October 2, 2026 after EUR 362.25.

Architektonischer 3D-Render eines modernen Biopharma-Gebäudes mit Glasfassade und gepflegter Grünanlage — Amgen Inc. (ISIN US0311621009) passend visualisiert als architektonischer Render einer modernen Biopharma-Forschungsanlage, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) was trading at EUR 364.45 at Lang & Schwarz on October 2, 2026 at 1:42 p.m. CEST, up 0.61 percent from the prior close of EUR 362.25. The latest catalyst is the company's positive Phase 3 result for dazodalibep in systemic Sjogren's disease, followed by a higher Jefferies target for Amgen stock.

Dazodalibep clears a key trial hurdle

According to Amgen on September 22, 2026, the OASIZ 301 study met its primary endpoint at Week 48. The company said improvement in the ESSDAI measure of systemic disease activity was observed as early as Week 4 and continued through Week 48.

The study enrolled approximately 621 people, giving the result a meaningful development scope while keeping the commercial question open. Amgen plans to present detailed data at a future medical meeting, and the separate Phase 3 OASIZ 303 study is expected to complete in the fourth quarter of 2026, according to the same company release.

Jefferies raises its target to USD 410

As Yahoo Finance reported on September 23, 2026, Jefferies raised its Amgen price target from USD 367.00 to USD 410.00 after the trial result. Jefferies also lifted its risk-adjusted peak-sales estimate for dazodalibep from USD 1.00 billion to USD 4.50 billion, while retaining a Hold rating.

The target revision is significant for the pipeline narrative, but the next trial remains an important milestone before the opportunity can be assessed across both Sjogren's patient groups. That distinction matters because the current evidence is clinical rather than revenue-producing.

Quarterly growth supports the pipeline story

According to MarketBeat on September 23, 2026, Amgen reported USD 10.05 billion in revenue and USD 6.29 in earnings per share for the second quarter of 2026. Revenue increased 9.50 percent from the second quarter of 2025, while earnings per share exceeded the USD 5.62 consensus by USD 0.67.

MarketBeat also reported 2026 earnings-per-share guidance of USD 22.30-23.50 and a consensus rating of Hold based on 30 ratings, including 11 Buy, 15 Hold, 3 Sell and 1 Strong Buy assessments. The average 12-month target in that survey was USD 381.32, below Jefferies' USD 410.00 target.

Amgen stock holds a measured market signal

Amgen stock was trading at EUR 364.45 at Lang & Schwarz on October 2, 2026 at 1:42 p.m. CEST, plus 0.61 percent versus the Lang & Schwarz prior close of EUR 362.25. The modest daily move leaves the clinical result and the next OASIZ readout as the clearest measurable drivers for the investment case.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.